Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HMPL-453 in Advanced Solid Tumors (China I/II)
CTR20170175Phase 2Completed
- Sponsor
- HUTCHMED
- Start
- Jul 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of fanregratinib in Nonhematologic neoplasms, transitional cell carcinoma (TCC), intrahepatic cholangiocarcinoma (ICC), mesothelioma, sponsored by HUTCHMED. Started Jul 2017; status: completed.
02
Drugs
fanregratinib
03
Conditions
Nonhematologic neoplasmstransitional cell carcinoma (TCC)intrahepatic cholangiocarcinoma (ICC)mesothelioma
Beyond the preview
Go deeper on CTR20170175.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20170175.